Stupina Tatiana

Ms. Stupina Tatiana


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2017 in Molecules
Verified
Journal Article
Open access
PDF file
NSNataliya Sanina
Nataliya Sanina
NSNatal’ya Shmatko
Natal’ya Shmatko
STStupina Tatiana
Stupina Tatiana
ABAnastasia Balakina
Anastasia Balakina
ATAlexei A. Terent’ev
Alexei A. Terent’ev
We studied effects of NO-donor iron nitrosyl complex with N-ethylthiourea ligand (ETM) on normal or tumor-derived cell lines. ETM was mildly toxic to most cell lines studied except the human glioma cell line A172 that proved to be highly sensitive to the complex and underwent cell death after ETM exposure. The high susceptibility of A172 cells to ETM was attributed to its NO-donor properties since no toxicity was detected for the N-ethylthiourea ligand.

11 October 2018 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
STStupina Tatiana
Stupina Tatiana
ABAnastasia Balakina
Anastasia Balakina
TKTatiana Kondrat’eva
Tatiana Kondrat’eva
GKGalina Kozub
Galina Kozub
NSNataliya Sanina
Nataliya Sanina
ATAlexei A. Terent’ev
Alexei A. Terent’ev
NO donating iron nitrosyl complex with 2-aminothiophenyl ligand (2-AmPh complex) was studied for its ability to cause cell death and affect nuclear factor kappa B (NF-κB) signaling. The complex inhibited viability of HeLa cells and induced cell death that was accompanied by loss of mitochondrial membrane potential and characteristic for apoptosis phosphatidylserine externalization. At IC50, 2-AmPh caused decrease in nuclear content of NF-κB p65 polypeptide and mRNA expression of NF-κB target genes encoding interleukin-8 and anti-apoptotic protein BIRC3. mRNA levels of interleukin-6 and anti-apoptotic protein BIRC2 encoding genes were not affected. Our data demonstrate that NO donating iron nitrosyl complex 2-AmPh can inhibit tumor cell viability and induce apoptosis that is preceded by impairment of NF-κB function and suppression of a subset of NF-κB target genes.

13 September 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
ABAnastasia Balakina
Anastasia Balakina
TPTatyana Prikhodchenko
Tatyana Prikhodchenko
VAVera Amozova
Vera Amozova
STStupina Tatiana
Stupina Tatiana
VMVictoriya Mumyatova
Victoriya Mumyatova
DMDenis Mishchenko
Denis Mishchenko
In the case of various pathologies, an imbalance between ROS generation and the endogenous AOS can be observed, which leads to excessive ROS accumulation, intensification of LPO processes, and oxidative stress. For the prevention of diseases associated with oxidative stress, drugs with antioxidant activity can be used. The cytotoxic, antioxidant, and NO-donor properties of the new hybrid compound B6NO (di(3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridinium) salt of 2-(nitrooxy)butanedioic acid) were studied. It was determined that B6NO chelates iron ions by 94%, which indicates B6NO’s ability to block the Fenton reaction. The hybrid compound B6NO inhibits the process of initiated lipid peroxidation more effectively than pyridoxine. It was shown that B6NO exhibits antioxidant properties by decreasing ROS concentration in normal cells during the oxidative stress induction by tert-Butyl peroxide. At the same time, the B6NO antioxidant activity on tumor cells was significantly lower. B6NO significantly increases the intracellular nitrogen monoxide accumulation and showed low cytotoxicity for normal cells (IC50 > 4 mM). Thus, the results indicate a high potential of the B6NO as an antioxidant compound.